The KEYNOTE-355 trial examined whether the addition of pembrolizumab would enhance the antitumor activity of chemotherapy, including taxanes and a nontaxane platinum-based regimen, in patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Findings from the study were published by Cortes et al in The New England Journal of Medicine.
